Whatever the underlying explanation, the results of this large outcome trial intype 2 diabetes mellitus rule out a class effect of DPP4 inhibitors on heartfailure events and are therefore reassuring regarding the safety of sitagliptinin patients with pre-existing heart failure or at high risk of heartfailure. This evidence concerns the gene DPP4 and heart failure.